• Je něco špatně v tomto záznamu ?

Primary hemostasis in patients treated with LDL-apheresis for severe familiar hypercholesterolemia: a prospective pilot trial using PFA-100 analysis to rationalize therapeutic LDL-apheresis procedure

M Blazek, M Blaha, M Pecka, V Blaha, V Masin, J Maly

. 2007 ; 12 (6) : 571-576.

Jazyk angličtina Země Velká Británie

Typ dokumentu hodnotící studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc11003788

Grantová podpora
NR8505 MZ0 CEP - Centrální evidence projektů

LDL-apheresis is a method of extracorporeal elimination of serum LDL-cholesterol used for treating patients with severe hyperlipidemia resistant to diet and pharmacotherapy. A practically applicable marker that may possibly be used to ascertain the efficacy of this treatment in lowering the activity of atherosclerosis are still to be found and remains an unresolved problem. Activity of primary hemostasis plays an important role in the process of developing atherosclerotic complications. This fact led us to hypothesize that the investigation of primary hemostatic activity might be a useful marker for monitoring LDL-apheresis efficacy. The aim of this work was to verify this hypothesis. METHODS AND PATIENTS: Commercial analyzer Dade Behring PFA-100, Germany (PFA, platelet function analysis) was used for all investigations. This analyzer enables quantitative measurement of platelet-mediated hemostasis in uncoagulated (citrated) blood. The method simulates platelet activation by mechanical stress (shear stress), and also simulates contact of platelets with collagen. A total of nine long-term treated patients with familial hypercholesterolemia were included in the study group (4 females and 5 males). Ages ranged from 17 to 59 years (average 46.4, median 55). Two patients had homozygous hypercholesterolemia. Eighteen sample pairs were examined using collagen/epinephrine (COL/EPI) membrane and 17 pairs were examined using collagen/ADP (COL/ADP) membrane, the total number of samples amounted to 70. RESULTS: Closure time (CT) values were prolonged after separation in all cases but CT prolongation was not statistically significant (p < 0.14). No differences between homozygous and heterozygous patients were found (p < 0.05). CONCLUSION: Investigation of primary hemostasis using PFA-100 analyzer is not a suitable marker and should not be used to determine the optimal intensity of individual LDL-apheresis procedures.

000      
02371naa 2200445 a 4500
001      
bmc11003788
003      
CZ-PrNML
005      
20131004105139.0
008      
110302s2007 xxk e eng||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Blažek, Martin, $d 1973- $7 xx0052609
245    10
$a Primary hemostasis in patients treated with LDL-apheresis for severe familiar hypercholesterolemia: a prospective pilot trial using PFA-100 analysis to rationalize therapeutic LDL-apheresis procedure / $c M Blazek, M Blaha, M Pecka, V Blaha, V Masin, J Maly
314    __
$a Department of Hematology, University Hospital in Hradec Kralove, Hradec Kralove, Czech Republic. blazemar@seznam.cz
520    9_
$a LDL-apheresis is a method of extracorporeal elimination of serum LDL-cholesterol used for treating patients with severe hyperlipidemia resistant to diet and pharmacotherapy. A practically applicable marker that may possibly be used to ascertain the efficacy of this treatment in lowering the activity of atherosclerosis are still to be found and remains an unresolved problem. Activity of primary hemostasis plays an important role in the process of developing atherosclerotic complications. This fact led us to hypothesize that the investigation of primary hemostatic activity might be a useful marker for monitoring LDL-apheresis efficacy. The aim of this work was to verify this hypothesis. METHODS AND PATIENTS: Commercial analyzer Dade Behring PFA-100, Germany (PFA, platelet function analysis) was used for all investigations. This analyzer enables quantitative measurement of platelet-mediated hemostasis in uncoagulated (citrated) blood. The method simulates platelet activation by mechanical stress (shear stress), and also simulates contact of platelets with collagen. A total of nine long-term treated patients with familial hypercholesterolemia were included in the study group (4 females and 5 males). Ages ranged from 17 to 59 years (average 46.4, median 55). Two patients had homozygous hypercholesterolemia. Eighteen sample pairs were examined using collagen/epinephrine (COL/EPI) membrane and 17 pairs were examined using collagen/ADP (COL/ADP) membrane, the total number of samples amounted to 70. RESULTS: Closure time (CT) values were prolonged after separation in all cases but CT prolongation was not statistically significant (p < 0.14). No differences between homozygous and heterozygous patients were found (p < 0.05). CONCLUSION: Investigation of primary hemostasis using PFA-100 analyzer is not a suitable marker and should not be used to determine the optimal intensity of individual LDL-apheresis procedures.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a separace krevních složek $x metody $7 D001781
650    _2
$a LDL-cholesterol $7 D008078
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a hemostáza $7 D006487
650    _2
$a lidé $7 D006801
650    _2
$a hypercholesterolemie $x terapie $7 D006937
650    _2
$a familiární kombinovaná hyperlipidemie $x terapie $7 D006950
650    _2
$a hyperlipidemie $x terapie $7 D006949
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a aktivace trombocytů $7 D015539
650    _2
$a vyšetření funkce trombocytů $x normy $x přístrojové vybavení $7 D010979
650    _2
$a financování organizované $7 D005381
655    _2
$a hodnotící studie $7 D023362
700    1_
$a Bláha, Milan, $d 1938- $7 xx0034440
700    1_
$a Pecka, Miroslav $7 ola2004212040
700    1_
$a Bláha, Vladimír, $d 1964- $7 xx0002944
700    1_
$a Mašín, Vladimír $7 xx0061146
700    1_
$a Malý, Jaroslav, $d 1946- $7 nlk19990073524
773    0_
$t Hematology $w MED00007956 $g Roč. 12, č. 6 (2007), s. 571-576
910    __
$a ABA008 $b x $y 6 $z 0
990    __
$a 20110329113531 $b ABA008
991    __
$a 20131004105658 $b ABA008
999    __
$a ok $b bmc $g 831153 $s 695811
BAS    __
$a 3
BMC    __
$a 2007 $b 12 $c 6 $d 571-576 $m Hematology $n Hematology $x MED00007956
GRA    __
$a NR8505 $p MZ0
LZP    __
$a 2011-3B/irme

Najít záznam